News

Vyvgart Hytrulo formulation available for generalized MG in US

The recently approved prefilled syringe formulation of Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) that offers the possibility of self-administration is now available in the U.S. for eligible adults with generalized myasthenia gravis (gMG) who have antibodies against acetylcholine receptors (AChRs). These ready-to-use syringes are intended to be…

Enrollment complete in Phase 2 trial testing DNTH103 for gMG

Enrollment is now complete for a Phase 2 clinical trial testing Dianthus Therapeutics‘ treatment candidate DNTH103 in people with generalized myasthenia gravis (gMG). According to the developer, the initial results from the global study, dubbed MAGIC (NCT06282159), are expected by early fall. MAGIC was launched early…

FDA approves J&J’s nipocalimab, now Imaavy, to treat gMG

The U.S. Food and Drug Administration (FDA) has approved nipocalimab as a treatment for adults and adolescents, ages 12 and older, with generalized myasthenia gravis (gMG) who have antibodies against the acetylcholine receptor (AChR) or muscle-specific kinase (MuSK) proteins. The newly approved therapy will be sold by developer…

Vyvgart outperforms standard treatment in real-world study

Vyvgart (efgartigimod alfa-fcab) is faster and more effective at reducing symptoms to a minimum than standard treatment with corticosteroids and/or immunosuppressants in adults with myasthenia gravis (MG), a real-world study showed. Data showed that Vyvgart was particularly effective at easing symptoms affecting muscles involved in breathing, speech, and…

Anti-MuSK antibody levels don’t reflect MG disease severity: Study

Levels of antibodies against muscle-specific kinase (MuSK) are not reflective of disease severity in people with MuSK-positive myasthenia gravis (MG), according to a study. “Given our results, MuSK autoantibodies are not suitable as biomarkers for clinical severity or prognosis in MuSK-positive MG,” the researchers wrote. The study, “…

Generalized MG severity tied to misdiagnosis, certain symptoms

People with generalized myasthenia gravis (gMG) who were misdiagnosed at least once and who have certain disease symptoms are more likely to see an increase in disease severity, according to a recent study. Ocular symptoms and/or muscle aches after physical activity were significantly associated with a higher risk of…

Rituximab treatment effective for 4-year-old’s MuSK-MG: Report

Rituximab may be safe and effective in treating young children with myasthenia gravis (MG) driven by antibodies that target muscle-specific tyrosine kinase (MuSK), according to a report detailing the case of a 4-year-old girl. The girl was one of the youngest MG patients to have received rituximab, according…

Diverse mechanisms found for myasthenia gravis’ AChR antibodies

Disease-causing antibodies from different myasthenia gravis (MG) patients bind to and affect the function of acetylcholine receptors (AChRs) in different ways, a study finds. While the mechanism varied, all the antibodies ultimately interfered with the usual activation of AChRs, which are the proteins important for normal muscle contractions commonly…

Symptoms of gMG controlled with long-term nipocalimab treatment

Long-term treatment with nipocalimab led to sustained reductions in symptom severity among antibody-positive patients with generalized myasthenia gravis (gMG) in a Phase 3 clinical trial. That’s according to new data presented by its developer, Johnson & Johnson, at the American Academy of Neurology (AAN) Annual Meeting this…